Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfenex, Agila Biotech to develop biosimilar products
As per the joint venture agreement, both the companies will equally share in decision making regarding product development and commercialization where in Agila Biotech will be a 51%
As per the joint venture agreement, both the companies will equally share in decision making regarding product development and commercialization where in Agila Biotech will be a 51%
The funds will support Immunovaccine’s RSV program advancement, including formulation of RSV antigens in DepoVax vaccine adjuvanting technology. Immunovaccine chief executive officer John Trizzino said at present there
The payment technology platforms will ensure that clinical trial payments from sponsor to site and from site to subjects are compliant with relevant regulations, including the Sunshine Act.
In 2009, the American Civil Liberties Union and the Public Patent Foundation filed a suit against Myriad Genetics that has patents for BRCA1 and BRCA2 genes, mutations coupled
The 29,000ft² laboratory in Singapore offers services to clients in South Korea, Taiwan, Hong Kong, the Philippines, Australia, and India. The service offerings include chemistry, immunology, hematology, flow
The Germany-based company registered the Injex30 with the help of its exclusive distributor Hangzhou Hema Medical Equipment. The approval process, which took more than 1.5 years, has required
In addition to the CRL, the multi-specialty health care company has already received draft labeling from the FDA and expects minimal revisions to the labeling. In the CRL,
Santaris’ proprietary Locked Nucleic Acid (LNA) drug platform will be used in the discovery and development of the novel medicines. The LNA Drug platform combines the company’s LNA
The efficacy of MM-121 in combination with paclitaxel compared to paclitaxel alone in the neoadjuvant setting of HER2-negative breast cancer will be assessed in the study. MM-121 is
As part of the expansion, the company is expecting to construct new facility for hormone development, clinical trial manufacturing and commercial manufacturing operations besides adding around 25 employees.